The use of artificial intelligence to develop new treatments has become a trend in the industry

[Pharmaceutical Network Industry News] With the rise of a new generation of information technology and the development of many high-tech fields, a series of cutting-edge technologies represented by artificial intelligence have begun to shine in various traditional fields.
Among them, the integration of artificial intelligence and the pharmaceutical industry has developed It's very eye-catching
.

Especially in the field of drug research and development, it is continuously providing strong help
.

It is understood that the reason for the rise of artificial intelligence in the field of medicine is mainly that the development of new drugs is a very long, inefficient and costly work
.

According to relevant data, the average research and development cost of a new drug is as high as 2.
6 billion US dollars, but even if it enters the clinical trial stage, only 12% of the drugs are eventually marketed
.

In this context, more and more pharmaceutical companies choose to apply artificial intelligence technology to save the cost and time of testing, strive to shorten the research and development process, reduce research and development costs, and improve the success rate of new drug research and development
.

For example, today, PathAI and GlaxoSmithKline (GSK) jointly announced that they have entered into a multi-year strategic research and development cooperation, which will use PathAI’s digital pathology technology platform (including its AIM-NASH tool) to accelerate oncology and non-alcoholic fatty Scientific research and drug development programs for hepatitis (NASH)
.

 　　For this cooperation, GSK said that it will use PathAI's expertise and models to promote the development of GSK's unique AI models, focusing on designing better models to bring improved treatment options for cancer and NASH patients
.

 　　Prior to this, Insilicon also announced a research and development cooperation with the translation team of the University of Zurich
.

Under the collaboration agreement, the MIKADO group will use its multi-omics database obtained from preclinical models and cellular models of cystinosis to identify patients with cystinosis through Insilico's AI target discovery platform PandaOmics Cellular and molecular pathways leading to life-threatening complications
.

 　　In addition to the above companies, Bayer, Pfizer, Novartis, AstraZeneca, Takeda and other companies have also begun to invest in and cooperate with artificial intelligence startups in order to increase their clinical support and obtain innovative drug structures
.

Among them, Merck has been betting on "artificial intelligence" with its health innovation fund and accelerator program since 2016
.

 　　Johnson & Johnson is also actively investing in artificial intelligence, conducting R&D strategic layout and innovative development, including expanding investment and cooperation in the field of surgical robots, and developing 3D printing to better improve surgical outcomes
.

In 2020, Johnson & Johnson announced that its Janssen pharmaceutical company has established a partnership with Insilico Medicine, a company focused on artificial intelligence drug discovery in JLABS Shanghai
.

 　　The analysis believes that the current investment in artificial intelligence by pharmaceutical companies has involved drug discovery, diagnosis, and nursing, covering almost the entire value chain of the pharmaceutical industry
.

In these aspects, while artificial intelligence will play an increasingly important role, the market space will also become larger and larger
.

According to IDC data, the total value of the artificial intelligence application market is expected to reach US$127 billion in 2025, of which the medical industry accounts for nearly 20% of the total application market
.


Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.